Natera Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于公司

公司简介

公司代码NTRA

公司名称Natera Inc

上市日期Jul 02, 2015

CEOMr. Steven Leonard (Steve) Chapman

员工数量4424

证券类型Ordinary Share

年结日Jul 02

公司地址13011 Mccallen Pass

城市AUSTIN

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编78753

电话16502499090

网址https://www.natera.com/

公司代码NTRA

上市日期Jul 02, 2015

CEOMr. Steven Leonard (Steve) Chapman

公司高管

名称

名称/职务

职务

持股

持股变动

Dr. Matthew Rabinowitz, Ph.D.

Executive Chairman of the Board, Co-Founder

2.32M

-1.69%

Mr. Roelof Frederick Botha

Lead Independent Director

1.23M

+0.01%

Mr. Jonathan Sheena

Co-Founder, Director

311.77K

-0.98%

Mr. Daniel A Rabinowitz

Secretary, Chief Legal Officer

151.45K

-1.05%

Mr. John Fesko

President, Chief Business Officer

88.14K

+1.14%

Herman Rosenman, CPA

Independent Director

65.67K

+0.23%

Mr. Solomon Moshkevich

President - Clinical Diagnostics

46.21K

-6.67%

Dr. Monica Bertagnolli, M.D.

Independent Director

6.13K

+1.79%

Mr. Steven Leonard (Steve) Chapman

Chief Executive Officer, Director

4.42K

-68.63%

Mr. Michael Burkes Brophy

Chief Financial Officer

4.36K

-53.71%

名称

名称/职务

职务

持股

持股变动

Dr. Matthew Rabinowitz, Ph.D.

Executive Chairman of the Board, Co-Founder

2.32M

-1.69%

Mr. Roelof Frederick Botha

Lead Independent Director

1.23M

+0.01%

Mr. Jonathan Sheena

Co-Founder, Director

311.77K

-0.98%

Mr. Daniel A Rabinowitz

Secretary, Chief Legal Officer

151.45K

-1.05%

Mr. John Fesko

President, Chief Business Officer

88.14K

+1.14%

Herman Rosenman, CPA

Independent Director

65.67K

+0.23%

收入明细

单位: USD更新时间: 7月6日周日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

业务USD

名称

营收

占比

Insurance carriers

472.65M

94.18%

Laboratory and other partners

20.83M

4.15%

Patients

8.35M

1.66%

地区USD

名称

营收

占比

United States

492.31M

98.10%

Europe, Middle East, India, Africa

6.05M

1.21%

Asia Pacific and Other

1.78M

0.36%

Americas, excluding U.S

1.69M

0.34%

业务

地区

业务USD

名称

营收

占比

Insurance carriers

472.65M

94.18%

Laboratory and other partners

20.83M

4.15%

Patients

8.35M

1.66%

股东统计

更新时间: 8月16日周六

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

9.20%

T. Rowe Price Associates, Inc.

8.79%

JP Morgan Asset Management

6.50%

BlackRock Institutional Trust Company, N.A.

4.94%

Farallon Capital Management, L.L.C.

3.51%

其他

67.06%

持股股东

占比

The Vanguard Group, Inc.

9.20%

T. Rowe Price Associates, Inc.

8.79%

JP Morgan Asset Management

6.50%

BlackRock Institutional Trust Company, N.A.

4.94%

Farallon Capital Management, L.L.C.

3.51%

其他

67.06%

股东类型

持股股东

占比

Investment Advisor

46.29%

Investment Advisor/Hedge Fund

27.68%

Hedge Fund

12.63%

Individual Investor

3.13%

Family Office

2.73%

Family Office

2.73%

Family Office

2.35%

Bank and Trust

1.98%

Research Firm

1.44%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

1137

131.96M

96.64%

-402.16K

2025Q1

1129

133.60M

97.90%

+2.21M

2024Q4

1001

128.40M

95.17%

-537.76K

2024Q3

896

125.06M

100.75%

-6.81M

2024Q2

850

125.13M

101.89%

-7.92M

2024Q1

798

124.30M

101.71%

-6.12M

2023Q4

781

119.55M

99.60%

-13.66M

2023Q3

787

122.52M

102.97%

-5.30M

2023Q2

792

116.72M

102.40%

-10.10M

2023Q1

788

115.81M

102.22%

-9.06M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

12.34M

9.04%

+53.13K

+0.43%

Mar 31, 2025

T. Rowe Price Associates, Inc.

10.43M

7.64%

+3.78M

+56.77%

Mar 31, 2025

JP Morgan Asset Management

6.39M

4.68%

+531.80K

+9.07%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

6.68M

4.89%

+212.90K

+3.29%

Mar 31, 2025

Farallon Capital Management, L.L.C.

4.55M

3.33%

+116.20K

+2.62%

Mar 31, 2025

State Street Global Advisors (US)

3.37M

2.47%

+379.58K

+12.69%

Mar 31, 2025

Duquesne Family Office LLC

3.40M

2.49%

-164.52K

-4.61%

Mar 31, 2025

Wellington Management Company, LLP

3.06M

2.24%

-180.35K

-5.57%

Mar 31, 2025

RTW Investments L.P.

2.59M

1.9%

+223.00

+0.01%

Mar 31, 2025

Geode Capital Management, L.L.C.

2.39M

1.75%

+153.28K

+6.87%

Mar 31, 2025

持股ETF

更新时间: 9月6日周六

机构名称

占比

Alger Weatherbie Enduring Growth ETF

6.31%

Franklin Genomic Advancements ETF

5.47%

ARK Genomic Revolution ETF

4.61%

VanEck Biotech ETF

4.36%

Alger Mid Cap 40 ETF

3.52%

First Trust NYSE Arca Biotechnology Index Fund

3.51%

Global X Genomics & Biotechnology ETF

3.46%

TrueShares Technology, AI & Deep Learning ETF

3.3%

First Trust Nasdaq Lux Digi Health Solutions ETF

3.29%

FT Raymond James Multicap Growth Equity ETF

2.66%

Alger Weatherbie Enduring Growth ETF

占比6.31%

Franklin Genomic Advancements ETF

占比5.47%

ARK Genomic Revolution ETF

占比4.61%

VanEck Biotech ETF

占比4.36%

Alger Mid Cap 40 ETF

占比3.52%

First Trust NYSE Arca Biotechnology Index Fund

占比3.51%

Global X Genomics & Biotechnology ETF

占比3.46%

TrueShares Technology, AI & Deep Learning ETF

占比3.3%

First Trust Nasdaq Lux Digi Health Solutions ETF

占比3.29%

FT Raymond James Multicap Growth Equity ETF

占比2.66%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Natera Inc

162.970USD

Natera Inc

162.970

概览

公司

财务

分析